JNJ Stock DD Johnson & Johnson 08/05/2014 17:00:29

New Post Public Reply Private Reply Replies (0) Message Board

Aug 5, 2014 at 6:00 PM

JNJ Johnson & Johnson $JNJ Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=JNJ&...mp;yt0=Go!

Last Updated: 08/05/2014 17:00:24

Current Price and Quotes
Last Price 99.82
Previous Close 100.16 Open 99.83
Daily Range 99.55 - 100.24 52wk Range 85.50 - 106.74
Volume 6,230,721 Dividend 2.80
Average Vol (3m) 6,212,462 Yield 2.8

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Jan 01, 2012 Jan 02, 2011
Total Revenue 71,312,000 67,224,000 65,030,000 61,587,000
Cost of Revenue 22,342,000 21,658,000 20,360,000 18,792,000
Gross Profit 48,970,000 45,566,000 44,670,000 42,795,000
Operating Expenses

Research and Development 8,183,000 7,665,000 7,548,000 6,844,000
Sales, General and Admin. 21,830,000 20,869,000 20,969,000 19,424,000
Non-Recurring Items 580,000 1,163,000 569,000 -
Other - - - -
Operating Income 18,377,000 15,869,000 15,584,000 16,527,000
Income From Continuing Operations

Add'l Income/Expense Items (2,424,000) (1,562,000) (2,652,000) 875,000
Earnings Before Interest and Tax 15,953,000 14,307,000 12,932,000 17,402,000
Interest Expense 482,000 532,000 571,000 455,000
Earnings Before Tax 15,471,000 13,775,000 12,361,000 16,947,000
Income Tax 1,640,000 3,261,000 2,689,000 3,613,000
Minority Interest - (339,000) - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 13,831,000 10,853,000 9,672,000 13,334,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 13,831,000 10,853,000 9,672,000 13,334,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 13,831,000 10,853,000 9,672,000 13,334,000

Recent News

Aug 4, 2014 Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen
Aug 3, 2014 Asia at Center of Global Wound Care Market Growth to 2019 Says a New Research Report Available with LifeScienceIndustryResearch.com
Aug 1, 2014 J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments P
Jul 31, 2014 CircleUp Announces Collaboration with Johnson & Johnson Innovation to Identify Transformative Consumer Companies
Jul 30, 2014 Dendreon Names W. Thomas Amick President and Chief Executive Officer
Jul 30, 2014 The Zacks Analyst Blog Highlights: Johnson & Johnson, Medtronic, Wright Medical Group, Cardinal Health and WellPoint
Jul 30, 2014 Aegerion Pharmaceuticals Appoints Craig Fraser as Chief Operating Officer
Jul 30, 2014 Power Morcellator Lawyers at Parilman & Associates Alert Public to Article Indicating That Manufacturers Knew of Product's Potential Cancer Risks for Years
Jul 30, 2014 Milestone Scientific Appoints Senior Healthcare Industry Executive Steven F. Robins as Marketing Consultant
Jul 30, 2014 Evotec Receives First Milestones in TargetAD Collaboration

1
2
3
4
5
6
7
8
next >
last >>

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...